Healthcare

Information date: 30 September 2026 — China regulates the collection, storage and outbound transfer of human genetic resources (HGR) and any international collaborative research using them. Foreign entities may not colle

Information date: 14 September 2026 — Health products entering China follow different routes depending on whether they are drugs, medical devices, in vitro diagnostics, cosmetics or health foods, and each route carries i

Information date: 1 September 2026 — China’s Ministry of Commerce said in April 2025 that authorities would accelerate pilot projects for foreign investment in wholly foreign-owned hospitals, alongside cloud computing an

Cross-border pharma-biotech deals involving Chinese companies surged past $48 billion in the first seven months of 2026. Here are 4 deal trends foreign pharma executives and investors need to track.

A record 10 brand-name drugs won bids in China's 10th round of centralized drug procurement on August 5, 2026, as NHSA introduced a dual-pathway selection mechanism. Here's the new market-access math for multinational pharmaceutical companies.

WuXi AppTec's shares surged 37% in H1 2026 as global GLP-1 weight-loss drug orders flooded China's CDMO sector. With peptide reactor capacity growing twelvefold to 100,000 liters, here's what the pharma manufacturing boom means for your foreign biotech or pharmaceutical business.